SCHEMBL13629417

SCHEMBL13629417

CCc1ccc(NS(=O)(=O)c2ccc(C(F)(F)F)cc2)cc1F

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.52
ALOX15 P16050 1/20 0.52
MAPK1 P28482 1/20 0.52
FFAR4 Q5NUL3 4/20 0.52
FFAR1 O14842 2/20 0.51
CDK1 P06493 1/20 0.51
CCNB1 P14635 1/20 0.51
CCNA2 P20248 1/20 0.51
CDK2 P24941 1/20 0.51
CDK7 P50613 1/20 0.51
CCNH P51946 1/20 0.51
CCNA1 P78396 1/20 0.51
BRD4 O60885 1/20 0.50
HDAC3 O15379 1/20 0.50
HDAC4 P56524 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC10 Q969S8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13629421 0.86 BRD4 (0.56) KMT2AMEN1ALOX15MAPK1FFAR4
SCHEMBL13629410 0.86 HSD17B2 (0.61) KMT2AFFAR4FFAR1CDK1CCNB1
SCHEMBL13629403 0.83 CES1 (0.58) KMT2AMEN1FFAR4FFAR1LMNA
SCHEMBL13629408 0.81 CDK1 (0.51) CDK1CCNB1CCNA2CDK2CDK7
SCHEMBL13615206 0.81 FFAR4 (0.60) KMT2AMEN1ALOX15MAPK1FFAR4
SCHEMBL13629400 0.81 CYP19A1 (0.61) KMT2AMEN1MAPK1FFAR4LMNA
SCHEMBL14601685 0.79 MEN1 (0.65) KMT2AMEN1ALOX15MAPK1BRD4
SCHEMBL17052984 0.78 FFAR4 (0.61) KMT2AMEN1MAPK1FFAR4FFAR1
SCHEMBL13629298 0.78 MEN1 (0.49) KMT2AMEN1LMNANPSR1MAPT
SCHEMBL13629426 0.76 SLC22A12 (0.74) BRD4HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK KMT2A 431/4885MEN1 1723/4885ALOX15 3117/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK KMT2A 439/4885MEN1 1920/4885ALOX15 3336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.